The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified - PubMed (original) (raw)
. 1993 Nov 1;53(21):5274-83.
Affiliations
- PMID: 8221662
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified
S M Freeman et al. Cancer Res. 1993.
Abstract
Tumor cells expressing the herpes simplex virus thymidine kinase (HSV-TK) gene are sensitive to the drug ganciclovir (GCV). We demonstrate here that HSV-TK-positive cells exposed to GCV were lethal to HSV-TK-negative cells as a result of a "bystander effect." HSV-TK-negative cells were killed in vitro when the population of cultured cells contained only 10% HSV-TK-positive cells. The mechanism of this "bystander effect" on HSV-TK-negative cells appeared to be related to the process of apoptotic cell death when HSV-TK-positive cells were exposed to GCV. Flow cytometric and electron microscopic analyses suggested that apoptotic vesicles generated from the dying gene-modified cells were phagocytized by nearby, unmodified tumor cells. Prevention of apoptotic vesicle transfer prevented the bystander effect. The toxic effect of HSV-TK-positive cells on HSV-TK-negative cells was reproduced in an in vivo model. A mixed population of tumor cells consisting of HSV-TK-positive and HSV-TK-negative cells was inoculated s.c. into mice. Regression of the tumor mass occurred when the inoculum consisted of as few as 10% HSV-TK-expressing tumor cells. The bystander effect was also demonstrated in i.p. tumor studies. Initial experiments demonstrated that prolonged survival (> 70 days) occurred when a mixture containing 50% HSV-TK-positive and 50% HSV-TK-negative cells was injected i.p. followed by GCV treatment. Further, survival was prolonged for mice with a preexisting HSV-TK-negative i.p. tumor burden by injecting HSV-TK-positive cells and GCV. These results suggest that genetic modification of tumor cells may be useful for developing cancer therapies.
Similar articles
- Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene.
Ramesh R, Munshi A, Abboud CN, Marrogi AJ, Freeman SM. Ramesh R, et al. Cancer Gene Ther. 1996 Nov-Dec;3(6):373-84. Cancer Gene Ther. 1996. PMID: 8988840 - [Bystander effect mediated by herpes simplex virus-thymidine kinase/ganciclovir approach on prostatic cancer cells and its regulation].
Xing Y, Lu G, Xiao Y, Zeng F, Zhang Q, Xiong P, Feng W. Xing Y, et al. Zhonghua Yi Xue Za Zhi. 2002 Nov 10;82(21):1484-7. Zhonghua Yi Xue Za Zhi. 2002. PMID: 12509912 Chinese. - Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice.
Yamamoto S, Suzuki S, Hoshino A, Akimoto M, Shimada T. Yamamoto S, et al. Cancer Gene Ther. 1997 Mar-Apr;4(2):91-6. Cancer Gene Ther. 1997. PMID: 9080117 - Influence of the bystander effect on HSV-tk/GCV gene therapy. A review.
van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA. van Dillen IJ, et al. Curr Gene Ther. 2002 Sep;2(3):307-22. doi: 10.2174/1566523023347733. Curr Gene Ther. 2002. PMID: 12189718 Review.
Cited by
- Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis.
Zhao JL, Lin BL, Luo C, Yi YL, Huang P, Chen Y, Zhao S, Huang ZJ, Ma XY, Huang L. Zhao JL, et al. J Transl Med. 2024 Nov 5;22(1):1000. doi: 10.1186/s12967-024-05794-4. J Transl Med. 2024. PMID: 39501324 Free PMC article. Review. - Biotin-cGMP and -cAMP are able to permeate through the gap junctions of some amacrine cells in the mouse retina despite their large size.
Yuan C, Gerhards L, Solov'yov IA, Dedek K. Yuan C, et al. Front Ophthalmol (Lausanne). 2024 Jan 15;3:1334602. doi: 10.3389/fopht.2023.1334602. eCollection 2023. Front Ophthalmol (Lausanne). 2024. PMID: 38983094 Free PMC article. - Programming tumor evolution with selection gene drives to proactively combat drug resistance.
Leighow SM, Reynolds JA, Sokirniy I, Yao S, Yang Z, Inam H, Wodarz D, Archetti M, Pritchard JR. Leighow SM, et al. Nat Biotechnol. 2024 Jul 4. doi: 10.1038/s41587-024-02271-7. Online ahead of print. Nat Biotechnol. 2024. PMID: 38965430 - Long-Term Follow-Up of Phase I Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy for Treatment of Metastatic Pancreatic Cancer.
Bhatnagar AR, Siddiqui F, Khan G, Pompa R, Kwon D, Nyati S. Bhatnagar AR, et al. Biomedicines. 2024 May 11;12(5):1065. doi: 10.3390/biomedicines12051065. Biomedicines. 2024. PMID: 38791027 Free PMC article. - ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Maris M, Salles G, Kim WS, Kim TM, Lyons RM, Arellano M, Karmali R, Schiller G, Cull E, Abboud CN, Batlevi C, Kagiampakis I, Rebelatto MC, Lee Y, Kirby LC, Wang F, Bothos J, Townsley DM, Fathi AT, Ribrag V. Maris M, et al. Target Oncol. 2024 May;19(3):321-332. doi: 10.1007/s11523-024-01054-z. Epub 2024 Apr 29. Target Oncol. 2024. PMID: 38683495 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources